Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Apr;64(4):537–543. doi: 10.1136/ard.2004.024927

Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNFα and IL18 but not CXCL12

M van Oosterhout 1, E Levarht 1, J Sont 1, T Huizinga 1, R Toes 1, J M van Laar 1
PMCID: PMC1755439  PMID: 15769913

Abstract

Background: Tumour necrosis α (TNFα) blocking agents lead to pronounced clinical effects and reduced synovial infiltrate in rheumatoid arthritis. Laboratory and clinical studies suggest that TNFα independent pathways play a role in the disease.

Objectives: To evaluate the immunopathological effects of combination therapy on rheumatoid synovial tissue in order to identify TNFα independent mechanisms.

Methods: 12 rheumatoid patients, including four DMARD (disease modifying antirheumatic drug) naive patients with early disease, were studied for the effect of combination therapy with infliximab and methotrexate on the synovial infiltrate. Biopsies and clinical assessments (DAS28) were carried out before the first and after the third infusion of infliximab. Synovial inflammation was scored semiquantitatively. Co-expression of CD38+ cells was studied by an immunofluorescent double labelling technique.

Results: Marked clinical responses were associated with a global reduction in the synovial infiltrate and expression of cytokines, notably interleukin 18 and TNFα, but low grade disease activity persisted. There was no effect on the expression of CXC chemokine ligand (CXCL12), and germinal centre-like structures were still detectable in synovial tissue in two patients after treatment. CD38+ activated T cells were more resistant to treatment than CD38+ plasma cells. No differences in clinical response or effects on synovial infiltrate were observed between DMARD refractory and DMARD naive patients.

Conclusions: Persistent expression of CXCL12 and incomplete resolution of lymphocytic infiltrates after infliximab plus methotrexate indicates that TNFα independent mechanisms are operative in rheumatoid arthritis. This may contribute to low grade disease activity, even in DMARD naive patients with early disease.

Full Text

The Full Text of this article is available as a PDF (296.4 KB).

Figure 1.

Figure 1

Open in a new tab

 Immunohistochemical analysis of the synovial infiltrate before (panels A, C, E, G) and after (panels B, D, F, H) three infusions of infliximab. Expression of CD38 (panels A and B), CD3 (panels C and D), IL18 (panels E and F), and CXCL12 (panels G and H). A–D, G, and H original magnification x100; E and F original magnification x250.

Figure 2.

Figure 2

Open in a new tab

 Immunofluorescent double staining in a DMARD refractory patient after treatment. FITC staining for CD3 (panels A and C) and CD138 (panels D and F). TRITC staining for CD38 (panels B and E) and double staining for CD38/CD3 (C) and CD38/CD138 (F). Original magnification x80. DMARD, disease modifying antirheumatic drug; FITC, fluorescein isothiocyanate; TRITC, tetramethylrhodamine isothiocyanate.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  2. Baeten D., De Keyser F., Veys E. M., Theate Y., Houssiau F. A., Durez P. Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules. Ann Rheum Dis. 2004 May;63(5):489–493. doi: 10.1136/ard.2003.012302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blades M. C., Ingegnoli F., Wheller S. K., Manzo A., Wahid S., Panayi G. S., Perretti M., Pitzalis C. Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice. Arthritis Rheum. 2002 Mar;46(3):824–836. doi: 10.1002/art.10102. [DOI] [PubMed] [Google Scholar]
  4. Bradfield Paul F., Amft Nicole, Vernon-Wilson Elizabeth, Exley Andrew E., Parsonage Greg, Rainger G. Ed, Nash Gerard B., Thomas Andrew M. C., Simmons David L., Salmon Mike. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum. 2003 Sep;48(9):2472–2482. doi: 10.1002/art.11219. [DOI] [PubMed] [Google Scholar]
  5. Buckley C. D. Michael Mason prize essay 2003. Why do leucocytes accumulate within chronically inflamed joints? Rheumatology (Oxford) 2003 Jun 27;42(12):1433–1444. doi: 10.1093/rheumatology/keg413. [DOI] [PubMed] [Google Scholar]
  6. Canetti Claudio A., Leung Bernard P., Culshaw Shauna, McInnes Iain B., Cunha Fernando Q., Liew Foo Y., Cannetti Claudio A. IL-18 enhances collagen-induced arthritis by recruiting neutrophils via TNF-alpha and leukotriene B4. J Immunol. 2003 Jul 15;171(2):1009–1015. doi: 10.4049/jimmunol.171.2.1009. [DOI] [PubMed] [Google Scholar]
  7. Dolhain R. J., Tak P. P., Dijkmans B. A., De Kuiper P., Breedveld F. C., Miltenburg A. M. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol. 1998 May;37(5):502–508. doi: 10.1093/rheumatology/37.5.502. [DOI] [PubMed] [Google Scholar]
  8. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  9. Ferrero E., Malavasi F. The metamorphosis of a molecule: from soluble enzyme to the leukocyte receptor CD38. J Leukoc Biol. 1999 Feb;65(2):151–161. doi: 10.1002/jlb.65.2.151. [DOI] [PubMed] [Google Scholar]
  10. Hitchon Carol, Wong Keng, Ma Guoping, Reed Jennifer, Lyttle David, El-Gabalawy Hani. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum. 2002 Oct;46(10):2587–2597. doi: 10.1002/art.10520. [DOI] [PubMed] [Google Scholar]
  11. Joosten Leo A. B., Radstake Timothy R. D., Lubberts Erik, van den Bersselaar Liduine A. M., van Riel Piet L. C. M., van Lent Peter L. E. M., Barrera Pilar, van den Berg Wim B. Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. 2003 Feb;48(2):339–347. doi: 10.1002/art.10814. [DOI] [PubMed] [Google Scholar]
  12. Kanbe Katsuaki, Takagishi Kenji, Chen Qian. Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4. Arthritis Rheum. 2002 Jan;46(1):130–137. doi: 10.1002/1529-0131(200201)46:1<130::aid-art10020>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  13. Klareskog Lars, van der Heijde Désirée, de Jager Julien P., Gough Andrew, Kalden Joachim, Malaise Michel, Martín Mola Emilio, Pavelka Karel, Sany Jacques, Settas Lucas. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675–681. doi: 10.1016/S0140-6736(04)15640-7. [DOI] [PubMed] [Google Scholar]
  14. Klimiuk P. A., Sierakowski S., Latosiewicz R., Cylwik J. P., Cylwik B., Skowronski J., Chwiecko J. Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis. 2003 May;62(5):472–475. doi: 10.1136/ard.62.5.472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  16. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  17. Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
  18. Nanki T., Hayashida K., El-Gabalawy H. S., Suson S., Shi K., Girschick H. J., Yavuz S., Lipsky P. E. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol. 2000 Dec 1;165(11):6590–6598. doi: 10.4049/jimmunol.165.11.6590. [DOI] [PubMed] [Google Scholar]
  19. Pablos José L., Santiago Begoña, Galindo María, Torres Carmen, Brehmer María T., Blanco Franciso J., García-Lázaro Francisco J. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol. 2003 Feb 15;170(4):2147–2152. doi: 10.4049/jimmunol.170.4.2147. [DOI] [PubMed] [Google Scholar]
  20. Park C. C., Morel J. C., Amin M. A., Connors M. A., Harlow L. A., Koch A. E. Evidence of IL-18 as a novel angiogenic mediator. J Immunol. 2001 Aug 1;167(3):1644–1653. doi: 10.4049/jimmunol.167.3.1644. [DOI] [PubMed] [Google Scholar]
  21. Pittoni V., Bombardieri M., Spinelli F. R., Scrivo R., Alessandri C., Conti F., Spadaro A., Valesini G. Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis. 2002 Aug;61(8):723–725. doi: 10.1136/ard.61.8.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Puren A. J., Fantuzzi G., Gu Y., Su M. S., Dinarello C. A. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest. 1998 Feb 1;101(3):711–721. doi: 10.1172/JCI1379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tak P. P., Smeets T. J., Daha M. R., Kluin P. M., Meijers K. A., Brand R., Meinders A. E., Breedveld F. C. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 1997 Feb;40(2):217–225. doi: 10.1002/art.1780400206. [DOI] [PubMed] [Google Scholar]
  24. Tak P. P., Taylor P. C., Breedveld F. C., Smeets T. J., Daha M. R., Kluin P. M., Meinders A. E., Maini R. N. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996 Jul;39(7):1077–1081. doi: 10.1002/art.1780390702. [DOI] [PubMed] [Google Scholar]
  25. Taylor P. C., Peters A. M., Paleolog E., Chapman P. T., Elliott M. J., McCloskey R., Feldmann M., Maini R. N. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000 Jan;43(1):38–47. doi: 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  26. Ulfgren A. K., Andersson U., Engström M., Klareskog L., Maini R. N., Taylor P. C. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum. 2000 Nov;43(11):2391–2396. doi: 10.1002/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  27. Wijdenes J., Vooijs W. C., Clément C., Post J., Morard F., Vita N., Laurent P., Sun R. X., Klein B., Dore J. M. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol. 1996 Aug;94(2):318–323. doi: 10.1046/j.1365-2141.1996.d01-1811.x. [DOI] [PubMed] [Google Scholar]
  28. van Gestel A. M., Prevoo M. L., van 't Hof M. A., van Rijswijk M. H., van de Putte L. B., van Riel P. L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996 Jan;39(1):34–40. doi: 10.1002/art.1780390105. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES